# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYINSTRUMENT ONLY TEMPLATE

Abbreviated submission for the clearance of a modification to the currently cleared CoaguChek XS Plus

# D. Type of Test or Tests Performed:

Prothrombin Time

# E. System Descriptions:

1. Device Description:

The Handheld Base Unit is an accessory to the CoaguChek XS Plus PT instrument that provides the ability to recharge the internal battery of the CoaguChek XS Plus and facilitates the connectivity of the CoaguChek XS Plus to an external computer in order to download the device memory.

2. Principles of Operation:

The HBU uses a POCT1-A protocol to identify a docked instrument in order to trigger the automatic host communication. Connectivity between the HBU and CoaguChek XS Plus is established either via infrared or IrDA.

3. Modes of Operation:

A switch (USB configuration switch), on the back side of the Handheld Base Unit, sets the BASE to one of three different modes of operation:

<table><tr><td rowspan=1 colspan=1>Position</td><td rowspan=1 colspan=1>Mode</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Ethernet</td><td rowspan=1 colspan=1>The BASE converts meter communication (IrDA)received on the BASE&#x27;s IR window to wiredEthernet.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Serial &amp;Ethernet</td><td rowspan=1 colspan=1>The BASE converts host communication (USBComm) to serial infrared on the BASE&#x27;s IRwindow.-or-The BASE converts meter communication (IrDA)received on the BASE&#x27;s IR window to wiredEthernet.Note: The BASE cannot handle Serial &amp; Ethernetconversion simultaneously. Both communicationpaths will be handled on after the other by meansof timeouts.</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Configuration</td><td rowspan=1 colspan=1>The BASE acts as a mass storage device on theUSB port. Writing and reading files, using themounted mass storage file system is the way tocommunicate with the BASE.</td></tr></table>

4. Specimen Identification: N/A

5. Specimen Sampling and Handling: N/A

6. Calibration: N/A

7. Quality Control: N/A

8. Software: FDA has reviewed applicants Hazard Analysis and Software Development processes for this line of product types: Yes___X____ or No_

# F. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>GJS</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>21 CFR 864.7750</td><td rowspan=1 colspan=1>81 Hematology</td></tr></table>

# G. Intended Use:

1. Indication(s) for Use:

The device is intended for use by professional healthcare providers for quantitative prothrombin time testing for the monitoring of warfarin therapy. The system uses fresh capillary or non-anticoagulated venous whole blood.

# 2. Special Conditions for Use Statement(s):

Prescription

# H. Substantial Equivalence Information:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Intended for use by professional healthcare providers forquantitativeprothrombin time testing for the monitoring of warfarintherapy. Thesystem uses fresh capillary or non-anticoagulated venouswhole blood.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring</td><td colspan="1" rowspan="1">0.8- 8.0 INR</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">range</td><td></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Human recombinant thromboplastin</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>RouterComponent:</td><td rowspan=1 colspan=1>HBU incorporates the routercomponentinto the HBU. Roche now has directdesign control of this component.</td><td rowspan=1 colspan=1>Connected to a hospitalnetwork via an off-the-shelfrouter component.</td></tr><tr><td rowspan=1 colspan=1>PhysicalCharacteristics</td><td rowspan=1 colspan=1>Serves as a docking station for thepredicate device.</td><td rowspan=1 colspan=1>Uses docking station forcharging and data transfer.</td></tr></table>

# I. Special Control/Guidance Document Referenced (if applicable):

<table><tr><td>STANDARDS</td></tr><tr><td>Title and Reference Number</td></tr><tr><td>Medical device software - Software life cycle processes (62304 Ed. 1.0)</td></tr></table>

<table><tr><td>Other Standards</td></tr></table>

<table><tr><td rowspan=1 colspan=4>GUIDANCE</td></tr><tr><td rowspan=1 colspan=1>Document Title</td><td rowspan=1 colspan=1>Office</td><td rowspan=1 colspan=1>Office Division</td><td rowspan=1 colspan=1>Web Page</td></tr><tr><td rowspan=2 colspan=1>Guidance for the Content ofPremarket Submissions forSoftware Contained in MedicalDevices - Guidance for Industryand FDA Staff</td><td rowspan=2 colspan=1>ODE</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/guidance/337.html</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

# J. Performance Characteristics:

1. Analytical Performance: a. Accuracy: N/A

b. Precision/Reproducibility: N/A   
c. Linearity: N/A   
d. Carryover: N/A   
e. Interfering Substances: N/A

2. Other Supportive Instrument Performance Data Not Covered Above:

# K. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# L. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.